Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.
Natural language processing (NLP) software correlated key characteristics expressed verbally in mammography reports with pathologic findings, providing an accurate indication for biopsy referral.
A novel sentinel lymph node (SLN) radiotracer, 99mTC-rituximab, demonstrated nearly 100% detection/success rate in SLN and metastasis in breast cancer.
Circulating tumor DNA (ctDNA) has shorter fragment sizes than DNA fragments from healthy cells that have died, and this may increase the clinical utility of liquid biopsies.
Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.
Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.
Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.
Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.
Analyzing tumor DNA fragments in the bloodstream, known as circulating tumor DNA (ctDNA), may offer a more complete view of a patient's cancer from a molecular perspective.
For smaller renal masses sized at 4 cm or less, mass biopsy is accurate.
Patients with suspected malignant melanoma or squamous cell carcinoma prefer other means to receive their biopsy results than face-to-face.
Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate CancerJanuary 19, 2016
An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Liquid biopsy of cerebrospinal fluid has potential for prognosis, treatment, identification, and tracking of brain tumor genomic alterations both in real time and over time.
Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate CancerNovember 25, 2015
Scientists developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug and which patients will not respond to the treatment in advance.
The mystery of unexpectedly low numbers of CTCs in a liquid biopsy may be explained by whether the blood is drawn from a vein or an artery.
New procedure allows doctors to collect cells from all along the esophagus, whereas standard biopsies take individual point samples.
Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detectionJune 08, 2015
A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.
This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.
Currently a skin biopsy can take approximately 30 minutes to perform, but a new device under development could reduce that time greatly.
Registered nurses in a bone marrow program maintained a 98% score for the quality of bone marrow aspiration and biopsy sample.
The use of breast ultrasound could eliminate the need for biopsy in many cases in adolescent girls, according to a recent study.
Study data suggests that magnetic resonance imaging (MRI) could one day make biopsies more effective, or even replace them altogether, via noninvasive detection of telltale sugar molecules shed by the outer membranes of cancerous cells.
A comparison of the diagnostic interpretation of breast biopsy slides by pathologists and that of an expert consensus panel yielded an overall agreement of 75%.
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small cell lung cancer as a surrogate for tumor biopsies.
Targeted magnetic resonance (MR)/ultrasound fusion biopsy outperformed standard biopsy technique for increased detection of high-risk prostate cancer, according to a recent study.
A new breast cancer risk model that combines histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer risk.
Prostate biopsies that combine both magnetic resonance imaging (MRI) technology and ultrasound appear to give more accurate results, according to a new study.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|